Online Controlled Substances Summit

Virtual Meeting
Public Session: July 25, 2024 | 11am-2pm (eastern)
Closed Working Session: July 26, 2024 | 11am-4pm (eastern)

Online Controlled Substances Summit SidebarThe sale of controlled substances over the internet poses significant health risks to consumers of all ages. Continued availability of controlled substances—such as opioids, benzodiazepines, and stimulants—through social media, websites, and other online platforms exacerbates public health concerns due to the heightened risks associated with the combined use of these products.

This fully virtual event, with two half-day sessions, will focus on identifying innovative solutions to reduce the availability of controlled substances online. Given the evolving online landscape for controlled substances, it is crucial that public and private stakeholders continue to develop effective strategies and innovative solutions that can combat this tremendous public health threat.

Join the Food and Drug Administration (FDA) and the Reagan-Udall Foundation for the FDA for the fifth Online Controlled Substances Summit.

See the Full Public Session Agenda

Review the Public Session Slides

View the Public Session Speaker Bios

Public Session Agenda

11am

Welcome

Susan C. Winckler, RPh, Esq., Reagan-Udall Foundation for the FDA

11:05am

Introductory Remarks

Robert M. Califf, MD, Commissioner of Food and Drugs, FDA

11:20am

Session 1: Perspectives from the FDA

Presenters:

  • Leigh Verbois, PhD, Director, Office of Drug Security, Integrity, and Response, Office of Compliance, Center for Drug Evaluation and Research, FDA
  • Dan Burke, Chief, Investigative Services Division, Office of Criminal Investigations, FDA

11:40am

Session 2: Perspectives from the Real World

Presenters:

  • Coreen Johnson, Senior Project Coordinator, Young People in Recovery
  • Chris Wilks, PhD, MPA, Senior Consultant, Health Management Associates

12pm

Session 3: Online Availability of Controlled Substances: A Snapshot

Presenters:

  • Murray Aitken, MBA, MCom, Executive Director, IQVIA Institute for Human Data Science
  • Justin Macy, PharmD, JD, Chair of Alliance for Safe Online Pharmacies (ASOP) Global Foundation
  • Angie Hoth, PharmD, MPH, Research Consultant, Reagan-Udall Foundation for the FDA

Reactor Panelists:

  • Kait Brown, PharmD, DABT, Clinical Managing Director, America's Poison Centers
  • Sean Fearns, Chief, DEA Community Outreach & Prevention Support, Office of Public Affairs

1pm

Session 4: Going Beyond the Message

Presenters:

  • Tim Mackey, MAS, PhD, Professor, University of California, San Diego
  • Erin Stack, MS, Director of Research and Evaluation, Comagine Health

1:15pm

Session 5: Perspectives from the Tech Sector

Panelists:

  • Megan Jones Bell, PsyD, Clinical Director for Consumer and Mental Health, Google
  • Amanda Plisner, JD, Senior Manager, Proactive Trust and Safety Operations, Snap Inc.
  • Ernest Voyard, JD, Director, Public Policy, Meta

1:55pm

Closing Remarks

Marta Sokolowska, PhD, Deputy Center Director, Substance Use and Behavioral Health, Center for Drug Evaluation and Research, FDA

2pm

Adjourn